4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.000p
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: 1,338.00p
  • 52 Week Low: 704.00p
  • Currency: UK Pounds
  • Shares Issued: 15.54m
  • Volume: 0
  • Beta: 0.03

Latest Deals

Traded Action Notifier PriceAmountValue
29-Sep-25 Buy Heikki Lanckriet 749.00p 2,000 £14,980.00
02-Apr-25 Buy Heikki Lanckriet 1,205.00p 2,400 £28,920.00
28-Feb-25 Buy Amy Walker 1,120.00p 1,151 £12,891.20
15-Nov-24 Buy Heikki Lanckriet 1,325.00p 46,500 £616,125.00
15-Nov-24 Sell Heikki Lanckriet 1,325.00p 46,500 £616,125.00

Largest Deals (365 days)

Traded Action Notifier PriceAmountValue
15-Nov-24 Sell Heikki Lanckriet 1,325.00p 46,500 £616,125.00
15-Nov-24 Buy Heikki Lanckriet 1,325.00p 46,500 £616,125.00
02-Apr-25 Buy Heikki Lanckriet 1,205.00p 2,400 £28,920.00
29-Sep-25 Buy Heikki Lanckriet 749.00p 2,000 £14,980.00
28-Feb-25 Buy Amy Walker 1,120.00p 1,151 £12,891.20

Director Shareholdings

Notifier Holding Value*
Heikki Lanckriet 1,119,688 £0
Amy Walker 44,016 £0
Hansjörg Plaggemars 6,667 £0

Major Shareholders

Notifier** Holding Value*
Wilhelm K. T. Zours 5,119,743 £0
DELPHI Unternehmensberatung AG 5,119,743 £0
4bb AG 5,115,852 £0
M&G Plc 4,627,741 £0
Elevage Medical Technologies Holdings 4,627,741 £0
Deutsche Balaton AG 4,432,637 £0
2invest AG 2,229,083 £0
Sparta AG 1,351,718 £0
Latonba AG 778,891 £0
Franciscus De Busschere 537,255 £0

* Value is calculated by using the current share price multiplied by the amount held.
** Major Shareholders are individuals or institutions that own more than 3% of the company’s shares and have been reported in the annual accounts.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 785.00p
Closing Price Change 0.000p
% Change 0.00 %
52 Week High 1,338.00p
52 Week Low 704.00p
Volume 0
Shares Issued 15.54m
Beta 0.03

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.49% below the market average65.49% below the market average65.49% below the market average65.49% below the market average65.49% below the market average
12.20% above the sector average12.20% above the sector average12.20% above the sector average12.20% above the sector average12.20% above the sector average
Price Trend
34.27% below the market average34.27% below the market average34.27% below the market average34.27% below the market average34.27% below the market average
4.55% above the sector average4.55% above the sector average4.55% above the sector average4.55% above the sector average4.55% above the sector average
Income Not Available
Growth
59.11% above the market average59.11% above the market average59.11% above the market average59.11% above the market average59.11% above the market average
65.52% above the sector average65.52% above the sector average65.52% above the sector average65.52% above the sector average65.52% above the sector average

4basebio Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page